


ASP5069




- ASP5069 is a drug candidate developed by astellas for the treatment of edema, hematoma and for the prevention of bleeding during surgery.
- It is a plasma kallikrein inhibitor, the serine protease responsible for the cleavage of kininogen into bradykinin.
- Bradykinin is a vasodilator that contributes to the activation of inflammation and the production of pain.
- Plasma kallikrein is also implicated in the expansion of chronic subdural hematoma and hyperglycemia-induced cerebral hematoma.



Reductive Amination:



Crystallization process for the API:



As the product crystallized the pH decreased requiring continual pH adjustments to achieve optimal yields

